

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

BBA



Europäisches Patentamt
European Patent Office
Office européen des brevets



⑪ Publication number : 0 515 144 A1

⑫

EUROPEAN PATENT APPLICATION

⑬ Application number : 92304530.6

⑮ Int. Cl. : A61K 31/505, A61K 31/52,
A61K 31/70

⑭ Date of filing : 19.05.92

⑯ Priority : 20.05.91 GB 9110874

⑰ Inventor : Bellessz, Bernard
431 Victoria Avenue
Westmount, Quebec H3Y 2R3 (CA)
Inventor : Nguyen-Ba, Nghe
175 Place Léontine Dubus
La Prairie, Quebec J5R 5M6 (CA)

⑭ Date of publication of application :
25.11.92 Bulletin 82/48

⑲ Representative : Ritter, Stephen David et al
Matthys & Squire 10 Fleet Street
London EC4Y 1AY (GB)

⑮ Designated Contracting States :
AT BE CH DE DK ES FR GB GR IT LI LU MC NL
PT SE

⑳ Applicant : BROCHEM PHARMA INC
2550 Daniel Johnson Boulevard, Suite 600
Laval, Quebec H7T 2J1 (CA)

㉑ 1,3-Oxazolidines useful in the treatment of hepatitis.

㉒ The present invention relates to the use of nucleoside analogues in the treatment of viral infections.
More specifically it is concerned with the use of 1,3-oxazolidine nucleoside analogues in the treatment
of hepatitis, in particular hepatitis B.


EP 0 515 144 A1

The present invention relates to the use of nucleoside analogues in the treatment of viral infections. More specifically it is concerned with the use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis, in particular hepatitis B.

Hepatitis B is a viral disease transmitted orally or parenterally by contaminated material such as blood and blood products, contaminated needles, sexually and vertically from infected or carrier mothers to their offspring. In those areas of the world where the disease is common, vertical transmission at an early age results in a high proportion of infected individuals becoming chronic carriers of hepatitis B. There are an estimated 250,000,000 carriers of hepatitis B worldwide. At the present time there are no effective chemotherapeutic agents for the treatment of hepatitis B infections.

European patent publication 0382526A describes a series of 1,3-oxathiolane nucleoside analogues having antiviral activity, in particular activity against HIV, the causative agent of AIDS. We have now found that certain of the compounds described in EP 0382526A are active both *in vitro* and *in vivo* against the hepatitis B virus.

The invention accordingly provides, in a first aspect, a method for the treatment of an animal, including man, infected with the hepatitis B virus comprising the administration of an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.





wherein R₁ is hydrogen or an acyl;

R₂ is a purine or pyrimidine base or an analogue or derivative thereof;

Z is S=O or SO₂;



provided that R₂ is not cytosine, when the compound of formula (I) is in the *cis* configuration, R₁ is hydrogen and Z is S=O.

It will be appreciated by those skilled in the art that the compounds of formula (I) contain at least two chiral centres (shown as • in formula (I)) and thus exist in the form of two pairs of optical isomers (i.e. enantiomers) and mixtures thereof including racemic mixtures. Thus the compounds of formula (I) may be either *cis* isomers, as represented by formula (II), or *trans* isomers, as represented by formula (III), or mixtures thereof. Each of the *cis* and *trans* isomers can exist as pairs of two enantiomers or as mixtures thereof including racemic mixtures. All such isomers and mixtures thereof including racemic mixtures are included within the scope of the invention.



The compounds of formula (I) are preferably in the form of their *cis* isomers.


It will also be appreciated that when Z is S=O the compounds exist in two additional racemic forms as shown in formulas (IIa) and (IIb) which differ in the configuration of the sulfoxide oxygen atom relative to the 2,5-substituents. The compounds of the invention additionally embrace such isomers and mixtures thereof.



• The purine or pyrimidin base R₁ will be linked at the 9- or 1-position respectively.

By purine or pyrimidine base or an analogue thereof is meant a purine or pyrimidine base found in nucleosides or an analogue thereof which mimics such bases in that their structures (the kinds of atoms and their arrangement) are similar to the normal bases but may either possess additional or lack certain of the functional properties of the normal bases. Such analogues include those derived by replacement of a CH₂ moiety by a nitrogen atom (for example, 5-azapyrimidines such as 5-azacytosine) or vice versa (for example 7-deazapurines, for example 7-deazadenosine or 7-deazaguanosine) or both (e.g. 7-deazadenosine or 7-deazaguanosine) or both (e.g. 7-deaza, 8-azapurines). By derivatives of such bases or analogues are meant those compounds wherein ring substituents are either incorporated, removed or modified by conventional substituents known in the art e.g. halogen, hydroxyl, amino, C₁₋₆ alkyl. Such purine or pyrimidine bases, analogues and derivatives will be well known to those skilled in the art.

Conveniently the group R₁ is selected from:




wherein R₂ is selected from the group consisting of: hydrogen and C₁₋₆ alkyl, unsubstituted or substituted with a heteroatom;

R₃ and R₄ are independently selected from the group consisting of: hydrogen, C₁₋₆ alkyl, bromine, chlorine, iodine, ~~nitro~~, and iodine;

R₅ is selected from the group consisting of: hydrogen, CN, carboxy, ethoxycarbonyl, carbamoyl and thiocarbamoyl; and

X and Y are independently selected from the group consisting of: bromine, chlorine, fluorine, iodine, amino and hydroxy groups.

Preferably R₅ is:



- 10 wherein R₃ and R₄ are as defined hereinabove.
Z is preferably -S-.
R₁ and R₂ are preferably hydrogen or C₁-₄ alkyl.
R₃ is preferably CH₃ or F.
- 15 X and Y are preferably both NH₂.
It will be appreciated by one skilled in the art that when R₁ is an acyl group, the compounds of formula (I) are esters. Preferred esters include a carboxy function R'-CO-O in which the non-carbonyl moiety R' is selected from hydrogen, straight or branched chain alkyl (e.g. methyl, ethyl, n-propyl, t-butyl, n-butyl), alkoxyalkyl (e.g., 20 methoxymethyl), aralkyl (e.g. benzyl), aryloxymethyl (e.g. phenoxymethyl), aryl (e.g. phenyl optionally substituted by halogen, C₁-₄ alkyl or C₁-₄ alkoxy); substituted dihydro pyridinyl (e.g. N-methyl dihydro pyridinyl); sulphonate esters such as alkyl- or aralkylsulphonyl (e.g. methanesulphonyl); sulfate esters, amino acid esters (e.g. L-valyl or L-isoleucyl) and mono-, di- or tri-phosphate esters.
- 25 Also included within the scope of such esters are esters derived from polyfunctional acids such as carboxylic acids containing more than one carboxyl group, for example, dicarboxylic acids HO₂C(CH₂)_nCO₂H where n is an integer of 1 to 10 (for example, succinic acid) or phosphonic acids. Methods for preparing such esters from the corresponding alcohol are well known. See, for example, Hahn et al., "Nucleotide Dimers as Anti Human Immunodeficiency Virus Agents", Nucleotide Analogues, pp. 158-159 (1988) and Stocco et al., "Nucleotide Dimers Suppress HIV Expression In Vitro", AIDS Research and Human Retroviruses, 4(6), pp. 449-453 (1988).
- 30 With regard to the above described esters, unless otherwise specified, any alkyl moiety present advantageously contains 1 to 16 carbon atoms, particularly 1 to 4 carbon atoms and could contain one or more double bonds. Any aryl moiety present in such esters advantageously comprises a phenyl group.
- 35 In particular the esters may be a C₁-₁₀ alkyl ester, an unsubstituted benzoyl ester or a benzoyl ester substituted by at least one halogen (bromine, chlorine, fluorine or iodine), C₁-₄ alkyl, saturated or unsaturated C₁-₄ alkoxy, nitro or trifluoromethyl groups.
- 40 By the term "pharmaceutically acceptable derivative" is meant any pharmaceutically acceptable salt of a compound of formula (I) or any other compound which, upon administration to the recipient, is capable of providing (directly or indirectly) a compound of formula (I) or an antivirally active metabolite or residue thereof.
- 45 It will be appreciated by those skilled in the art that the compounds of formula (I) may be modified to provide pharmaceutically acceptable derivatives thereof, at functional groups in both the base moiety and at the R₄ group of the oxazolidine ring. Modification at all such functional groups are included within the scope of the invention.
- 50 Pharmaceutically acceptable salts of the compounds of formula (I) include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acids include hydrochloric, hydrobromic, sulphuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulphonic, tartaric, acetic, citric, methanesulphonic, formic, benzoic, malonic, naphthalene-2-sulphonic and benzene-sulphonic acids. Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
- 55 Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and NR₄⁺ (where R is C₁-₄ alkyl) salts.
- 60 References hereinafter to a compound according to the invention includes both the compound of formula (I) and its pharmaceutically acceptable derivatives.
- 65 Specific compounds of formula (I) include:
- trans-2-hydroxymethyl-5-(cytosin-1'-yl)-1,3-oxa-4-olane;
cis-2-benzoyloxymethyl-5-(cytosin-1'-yl)-1,3-oxazolidane, trans-2-benzoyloxymethyl-5-(cytosin-1'-yl)-1,3-oxazolidane, and mixtures thereof;
- 70 cis-2-hydroxymethyl-5-(N₄'-acetyl-cytosin-1'-yl)-1,3-oxazolidane, trans-2-hydroxymethyl-5-(N₄'-acetyl-

cytosin-1'-yl)-1,3-oxathiolane, and mixtures thereof;

cis-2-benzoyloxymethyl-5-(N₄'-acetyl-cytosin-1'-yl)-1,3-oxathiolane, trans-2-benzoyloxymethyl-5-(N₄'-

acetyl-cytosin-1'-yl)-1,3-oxathiolane, and mixtures thereof;

cis-2-benzoyloxymethyl-5-(N₄'-acetyl-5-fluorocytosin-1'-yl)-1,3-oxathiolane, trans-2-benzoyloxymethyl-

5 -methyl-5-(N₄'-acetyl-5-fluorocytosin-1'-yl)-1,3-oxathiolane, and mixtures thereof;

cis-2-hydroxymethyl-5-(5'-fluorocytosin-1'-yl)-1,3-oxathiolane, trans-2-hydroxymethyl-5-(5'-fluorocytosin-

10 1'-yl)-1,3-oxathiolane, and mixtures thereof;

- cis-2-hydroxymethyl-5-(cytosin-1'-yl)-3-oxo-1,3-oxathiolane;

cis-2-hydroxymethyl-5-(thymine-N-1'-yl)-1,3-oxathiolane; and

15 cis-2-hydroxymethyl-5-(N,N-dimethylaminomethoxyenecytosin-1'-yl)-1,3-oxathiolane;

in the form of a racemic mixture or a single enantiomer.

The compounds of formula (I) are preferably in the form of the cis compounds and contain two chiral centres (shown in formula (I) by *) .

The compound of formula (I) is preferably in the form of a racemic mixture or a single enantiomer but a mixture of enantiomers in any ratio may be employed in the invention. Most preferably, the compound of formula (I) is in the form of its (-) enantiomer.

The compounds of formula (I) and their individual enantiomers may be prepared by any method known in the art for the preparation of compounds of analogous structure for example by the methods described in European patent publication 0382528A.

In a further or alternative aspect there is provided a compound of formula (I) as defined hereinabove or a pharmaceutically acceptable derivative thereof for use in the manufacture of a medicament for the treatment of hepatitis B.

As will be appreciated by those skilled in the art, references herein to treatment extend to prophylaxis as well as to the treatment of established infections or symptoms.

25 The compounds of formula (I) both as the racemic mixture and as the individual enantiomers have been found to inhibit the hepatitis B virus both *in vitro* and *in vivo*.

It will be appreciated that the amount of a compound of the invention required for use in treatment will vary not only with the particular compound selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attending physician or veterinarian. In general however a suitable dose will be in the range of from about 0.1 to about 750 mg/kg of bodyweight per day preferably in the range of 0.5 to 60 mg/kg/day, most preferably in the range of 1 to 20 mg/kg/day.

The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example as two, three, four or more sub-doses per day.

30 The compound is conveniently administered in unit dosage form; for example containing 10 to 1500 mg, conveniently 20 to 1000 mg, most conveniently 50 to 700 mg of active ingredient per unit dosage form.

Ideally the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 1 to about 75 μ M, preferably about 2 to 50 μ M, most preferably about 3 to about 30 μ M. This may be achieved, for example, by the intravenous injection of a 0.1 to 5% solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 1 to about 100 mg of the active ingredient. Desirable blood levels may be maintained by a continuous infusion to provide about 0.01 to about 5.0 mg/kg/hour or by intermittent infusions containing about 0.4 to about 15 mg/kg of the active ingredient.

While it is possible that, for use in therapy, a compound of the invention may be administered as the raw chemical it is preferable to present the active ingredient as a pharmaceutical formulation.

35 The invention thus further provides a pharmaceutical formulation comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof together with one or more pharmaceutically acceptable carriers therefor and, optionally, other therapeutic and/or prophylactic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

40 Pharmaceutical formulations include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, sub-cutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation. The formulations may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the active compound with liquid carriers, or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.

45 Pharmaceutical formulations suitable for oral administration may conveniently be presented as discrete units such as capsules, capsules or tablets each containing a predetermined amount of the active ingredient as a powder or granules; as a solution, a suspension or as an emulsion. The active ingredient may also be

presented as a bolus, electuary or paste. Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents. The tablets may be coated according to methods well known in the art. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), or preservatives.

The compounds according to the invention may also be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.

For topical administration to the epidermis the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents.

Formulations suitable for topical administration in the mouth include lozenges comprising active ingredient in a flavored base, usually sucrose and acacia or gum tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

Pharmaceutical formulations suitable for rectal administration wherein the carrier is a solid are most preferably presented as unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art, and the suppositories may be conveniently formed by admixture of the active compound with the softened or melted carrier(s) followed by chilling and shaping in moulds.

Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

For intra-nasal administration the compounds of the invention may be used as a liquid spray or dispersible powder or in the form of drops.

Drops may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, solubilizing agents or suspending agents. Liquid sprays are conveniently delivered from pressurized packs.

For administration by inhalation the compounds according to the invention are conveniently delivered from an insufflator, nebulizer or a pressurized pack or other convenient means of delivering an aerosol spray. Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, nitrogen or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount.

Alternatively, for administration by inhalation or insufflation, the compounds according to the invention may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form in, for example, capsules or cartridges or e.g. gelatin or bi-layer packs from which the powder may be administered with the aid of an inhalator or insufflator.

When desired the above described formulations adapted to give sustained release of the active ingredient may be employed.

The pharmaceutical compositions according to the invention may also contain other active ingredients such as antimicrobial agents, or preservatives.

The compounds of the invention may also be used in combination with other therapeutic agents for example other antiviral agents. In particular the compounds of the invention may be employed together with known antiviral, antibacterial, antifungal or immunomodulating agents.

The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a physiologically acceptable derivative thereof together with another therapeutically active agent, in particular an antiviral, antibacterial, antifungal or immunomodulating agent.

The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier therefor comprise a further aspect of the invention.

The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.

When a compound of formula (I) or a pharmaceutically acceptable derivative thereof is used in combination with a second therapeutic agent active against the same virus the dose of each compound may be either the same as or differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.

The invention is illustrated by the following examples which should not be interpreted as a limitation of the invention.

10 Example 1

Cis- and trans-2-benzoyloxymethyl-5-(N₄'-acetyl-5'-fluoro-cytosin-1'-yl)-1,3-oxathiolane

15 5-Fluorocytosine (4.30 g, 33.3 mmol), hexamethyldisilazane (25 ml) and ammonium sulfate (120 mg) were boiled under reflux until the cytosine dissolved (3 hours) and then further refluxed for 2 hours. The hexamethyldisilazane is evaporated in vacuo and toluene (100 ml) was added to the residue to co-evaporate the solvent. The resulting solution, bis(trimethylsilyl)-fluoro-cytosine in dichloromethane (40 ml) was added under argon to a solution of 2-benzoyloxymethyl-5-acetyl-1,3-oxathiolane (8.537 g, 30.3 mmol) in dry dichloromethane (100 ml) and molecular sieves (4A, 2 g) previously prepared under argon and cooled at 0°C for 20 minutes. (Trifluoromethane-sulfonyl)oxytrimethylsilane (8 ml, 31 mmol) was added to this mixture at 0°C and the resulting solution was stirred at 25°C for approximately 18 hours. The reaction mixture was then treated with 300 ml of saturated solution of sodium bicarbonate and stirred at room temperature for 2 hours. The filtrate was shaken two times with 300 ml of brine and one time with distilled water. The organic layer was dried over magnesium sulfate, filtered and evaporated to dryness. This afforded a crude 5-fluoro-cytosine derivative (10.1 g). R_f: 0.57 (EtOAc:MeOH 9:1).

20 This residue was acetylated in the next step without further purification. The crude material was dissolved in dry dichloromethane (120 ml) in a 500 ml round bottom flask under argon. Triethylamine (12.7 ml, 91.9 mmol) and dimethyl aminocytidine (111 mg, 0.8 mmol) were added to the solution. The flask was then immersed in an ice bath for 1 hour under argon. Acetic anhydride (4.3 ml, 45 mmol), dried over sodium acetate, was syringed into the cooled flask. The mixture was stirred overnight and then carefully decanted into an Erlenmeyer flask containing saturated sodium bicarbonate solution. The product was then washed with distilled water followed by brine solution. The methylene chloride portions were dried and evaporated under high vacuum to dryness, yielding an acetylated α/β mixture as a colorless foam, weighing 9.8 g after drying. Flash chromatography of this material using ethylacetate:methanol (9:1) afforded 3.1 g, 7.8 mmol (46%) pure trans-(benzoyloxymethyl-5-(N₄'-acetyl-5'-fluoro-cytosin-1'-yl)-1,3-oxathiolane) and 3.5 g, 8.9 mmol (30%) pure cis-(benzoyloxymethyl-5-(N₄'-acetyl-5'-fluoro-cytosin-1'-yl)-1,3-oxathiolane).

25 trans-isomer: R_f: 0.66 in ethyl acetate:methanol 9:1

U.V.: (MeOH) Lambda max: 308 nm

¹H-NMR δ (ppm in CDCl₃)

30 8.77 (b, 1H; C_{6'}-NH-Ac)
8.08 (m, 2H; aromatic)
7.70 (d, 1H; C_{6'}-H, J_{ar}=8.3Hz)
7.62 (m, 1H; aromatic)
7.49 (m, 2H; aromatic)

35 6.51 (dd, 1H; C_{7'}H)
5.91 (dd, 1H; C_{7'}H)
4.48 (dd, 2H; C_{7'}-CH₂-OCOC₂H₅)
3.88 (dd, 1H; C_{6'}-H)
3.34 (dd, 1H; C_{6'}-H)

40 2.58 (s, 3H; NH-COCH₃)
cis-isomer: R_f: 0.58 in ethyl acetate:methanol 9:1

U.V.: (MeOH) Lambda max: 309nm

¹H-NMR δ (ppm in CDCl₃)

45 8.72 (b, 1H; C_{6'}-NH-Ac)
8.06 (m, 2H; aromatic)
7.97 (d, 1H; C_{6'}-H, J_{ar}=8.2Hz)
7.50 (m, 1H; aromatic)
7.49 (m, 2H; aromatic)

8.32 (dd, 1H; C_{4'}-H)
 5.47 (dd, 1H; C_{4'}-H)
 4.73 (dd, 2H; C_{2'}-CH₂-OCOC₆H₅)
 3.82 (dd, 1H; C_{6'}-H)
 3.19 (dd, 1H; C_{6'}-H)
 2.55 (s, 3H; NH-COCH₃)

Example 210 Cle- and trans-hydroxymethyl-5-(5'-fluorocytosin-1'-yl)-1,3-oxazolidine

1.0 g (2.54 mmol) of *trans*-2-benzoyloxymethyl-5-(N₄'-acetyl-5'-fluorocytosin-1'-yl)-1,3-oxazolidine was stirred in 25 ml of methanolic ammonia at 0° for 1 hour and then overnight at room temperature. The mixture was evaporated under reduced pressure. The residue was titrated twice (2 x 30 ml) with anhydrous ether. The solid residue was recrystallized in absolute ethanol to give 484 mg (1.95 mmol, 77%) of desired product *trans*-hydroxymethyl-5-(5'-fluorocytosin-1'-yl)-1,3-oxazolidine; m.p. 219-221°C; R=0.21 in ethyl acetate: methanol (9:1), which was identified by ¹H, ¹³C-NMR and U.V. Lambda max (H₂O) 280.9 nm.

1.2 g (3.05 mmol) of *cis*-2-benzoyloxymethyl-5-(N₄'-acetyl-5'-fluoro-cytosin-1'-yl)-1,3-oxazolidine was stirred in 30 ml of methanolic ammonia at 0°C for 1 hour and then overnight at room temperature. The mixture was evaporated under reduced pressure. The residue was titrated twice (2 x 30 ml) with anhydrous ether. The solid residue was recrystallized in absolute ethanol to give 665 mg (2.84 mmol, 87%) of pure product *cis*-hydroxymethyl-5-(5'-fluorocytosin-1'-yl)-1,3-oxazolidine; m.p. 204-206°C; R=0.21 in ethyl acetate: methanol (9:1). The desired compound was identified by ¹H, ¹³C-NMR and U.V. Lambda max (H₂O) 280.9 nm. *trans*-isomer.

28 ¹H-NMR δ (ppm in DMSO-d₆):
 7.85 (d, 1H; C_{4'}-H, J_{CP}=7.01 Hz)
 7.83 (d, 2H; C_{6'}-NH₂)
 6.30 (dd, 1H; C_{2'}-H)
 5.80 (t, 1H; C_{6'}-H)
 5.18 (t, 1H; C_{2'}-CH₂-OH)
 3.49 (m, 3H; C_{2'}-CH₂-OH+CH₃)
 3.17 (dd, 1H; C_{4'}-H)

30 ¹³CNMR (DMSO-d₆). (Varian XL 300); δ in ppm

	C _{2'}	C _{4'}	C _{3'}	C _{6'}
28	153.47	158.20	134.65	126.24
	(² J _{CP} =13.2 Hz)	(J _{CP} =26.2 Hz)	(² J _{CP} =32.0 Hz)	

	C ₃	C ₄	C ₂	CH ₂ OH
28	88.20	36.18	87.16	64.71

46 cis-isomer:

1H-NMR δ (ppm in DMSO-d₆):
 8.22 (d, 1H; C_{4'}-H, J_{CP}=7.28 Hz)
 7.843 (d, 2H; C_{6'}-NH₂)
 8.18 (t, 1H; C_{2'}-H)
 5.43 (t, 1H; C_{2'}-CH₂-OH)
 5.19 (t, 1H; C_{2'}-H)
 3.77 (m, 2H; C_{2'}-CH₂-OH)
 3.35 (dd, 1H; C_{4'}-H)
 3.12 (dd, 1H; C_{6'}-H)

58 ¹³CNMR (DMSO-d₆)

C_3'	C_4'	C_5'	C_6'
153.46	158.14	134.63	126.32
		($J_{CP} = 14.0$ Hz)	($J_{CP} = 24.1$ Hz)
			($J_{CP} = 32.5$ Hz)
C_3	C_4	C_5	CH_3OH
86.82	36.80	86.77	62.32

10

Example 3Biological Results

18

(A) Newborn ducklings were infected with duck hepatitis B virus (DHBV). After 5 to 7 days post-infection, samples of blood were taken from the ducklings and examined for DHBV DNA using dot hybridization with a specific DNA probe (Mason et al., *Proc. Natl. Acad. Sci. USA* 79, pp. 3997-4001 (1982)). The livers were removed from dot-blot positive ducklings and used to produce primary hepatocyte cultures infected with DHBV as previously described (Tuttleman et al., *J. of Virology*, 58, pp. 17-25). After 2 days in culture, antiviral agents were added to the culture media. The media were changed every 2 days and at selected times, the cells were removed and the total DNA extracted.

19

The DNA was spotted on nitrocellulose paper and probed with the ^{32}P -labelled DHBV DNA probe in accordance with the following procedure. The DNA from DHBV-infected hepatocytes was extracted and spotted onto a nitrocellulose filter. The above described ^{32}P -nick translated-DHBV DNA ($pOD-010 = DHBV$) probe was used. The DNA was extracted from 6-cm cell culture dishes at various times post-plating. In the virus control (VC) group, cells were harvested at 2, 6, 8, 10, 14, 18 and 20 days. Duplicate samples were spotted for days 14, 18 and 20. In drug-treated groups, cells were harvested on days 8, 14 and 20. Drugs were added to the culture at 2 days post-plating and maintained throughout media changes every 2 days. The total intracellular DNA was extracted from cells using the standard phenol extraction method. The cells in a 6-cm diameter Petri dish (approximately 5×10^6 cells) were lysed in a lysis buffer containing 0.2% SDS, 150 mM Tris-HCl pH 8.0, 10 mM EDTA, 5 mM EGTA, and 150 mM NaCl. The cell lysate was digested with 0.5 mg/ml of proteinase K (available from Sigma) at 37°C for 2 hours and proteinized by extraction with an equal volume of phenol saturated with 20 mM Tris-HCl, pH 7.5, 0.5 mM EDTA and 0.1% 8-hydroxyquinaline. Concentrated ammonium acetate (pH 7.0 (2.5 M)) was added to the aqueous phase to yield a 0.25 M ammonium acetate solution and the nucleic acids were precipitated with 2 volumes of 100% ethanol. The pellet of nucleic acid was washed with ethanol and dried. The DNA was dissolved in a solution containing 12.5 mM Tris-HCl, pH 7.5, 10 mM EDTA, 30% glycerol and 0.01% bromophenol blue. One tenth of the DNA sample was spotted onto the nitrocellulose for dot-blot analysis.

20

The drugs tested were scored on a scale of 0 (no activity) to ++++ (high activity).

21

The compounds tested were 1,3 oxathiolanes and two known inhibitors of hepatitis B, 2',3'-dideoxy-guanosine (ddG) and 2',6-diaminopurine-9-β-D-2',3'-dideoxyribonucleoside (ddCPR)-(European Patent publication 0302760A).

The results are shown in Table 1.

22

23


56

Table I

Compound	Activity
trans-2-hydroxymethyl-5-(5'-fluorocytosin-1'-yl)-1,3-oxathiolane	+
cis-2-hydroxymethyl-5-(5'-fluorocytosin-1'-yl)-1,3-oxathiolane	+++
cis-2-hydroxymethyl-5-(thymine-N-1'-yl)-1,3-oxathiolane	++
cis-2-hydroxymethyl-5-(N,N-dimethylamino-methylene cytosin-1'-yl)-1,3-oxathiolane	++++
ddG	++++
ddDAPR	++++

Claims

1. Use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of a hepatitis B infection.



wherein R₁ is hydrogen or an acyl;


R₂ is a purine or pyrimidine base or an analogue or derivative thereof; and

Z is S, S=O, or SO₂;

provided that R₂ is not cytosine when the compound of formula (I) is in the cis configuration, R₁ is hydrogen and Z is S.

2. The use according to claim 1, wherein the ester is selected from the group consisting of: R-CO-O-, wherein R is selected from hydrogen, straight or branched alkyl, alkoxyalkyl, aralkyl, arylalkoxyalkyl, aryl, and substituted dihydrogyridimyl; sulphonate esters; sulfate esters; amino acid esters; mono-, di- or tri-phosphate esters; esters of polyfunctional acids; and esters of phosphoric acids.

3. The use according to claim 1, wherein Z is S.
4. The use according to claim 1, wherein R₂ of formula (I) is selected from the group consisting of:




wherein R₂ is selected from the group consisting of hydrogen and C₁₋₄ alkyl, unsubstituted or substituted with a heterocyclic;

R₄ and R₅ are independently selected from the group consisting of hydrogen, C₁₋₄ alkyl, bromine, chlorine, fluorine, and iodine;

R₆ is selected from the group consisting of hydrogen, CN, carbonyl, ethoxycarbonyl, carbamoyl and thiocarbamoyl; and

X and Y are independently selected from the group consisting of bromine, chlorine, fluorine, iodine, amino and hydroxy groups.

5. The use according to claim 4, wherein R₂ is



wherein R₃ is selected from the group consisting of hydrogen and C₁₋₄ alkyl unsubstituted or substituted with a heteroatomic; and
R₄ is selected from the group consisting of hydrogen, C₁₋₄ alkyl and bromine, chlorine, fluorine, and iodine.

- 11
- 6. The use according to claim 4 wherein R₃ and R₄ are hydrogen or C₁₋₄ alkyl.
 - 7. The use according to claim 4, wherein R₃ is CH₃ or F.
 - 8. The use according to claim 4, wherein X and Y are both NH₂.
 - 9. The use according to claim 1, wherein the compound is selected from the group consisting of: trans-2-hydroxymethyl-5-(cytosin-1'-yl)-1,3-oxathiolane; cis-2-benzoyloxymethyl-5-(cytosin-1'-yl)-1,3-oxathiolane, trans-2-benzoyloxymethyl-5-(cytosin-1'-yl)-1,3-oxathiolane, and mixtures thereof;
 - 10. cis-2-hydroxymethyl-5-(N⁴-acetyl-cytosin-1'-yl)-1,3-oxathiolane, trans-2-hydroxymethyl-5-(N⁴-acetyl-cytosin-1'-yl)-1,3-oxathiolane, and mixtures thereof;
 - 11. cis-2-benzoyloxymethyl-5-(N⁴-acetyl-5-fluorocytosin-1'-yl)-1,3-oxathiolane, trans-2-benzoyloxymethyl-5-(N⁴-acetyl-5-fluorocytosin-1'-yl)-1,3-oxathiolane, and mixtures thereof;
 - 12. cis-2-hydroxymethyl-5-(5'-fluorocytosin-1'-yl)-1,3-oxathiolane, trans-2-hydroxymethyl-5-(5'-fluorocytosin-1'-yl)-1,3-oxathiolane, and mixtures thereof;
 - 13. cis-2-hydroxymethyl-5-(cytosin-1'-yl)-3-oxo-1,3-oxathiolane;
 - 14. cis-2-hydroxymethyl-5-(thymin-N-1'-yl)-1,3-oxathiolane; and
 - 15. cis-2-hydroxymethyl-5-(N,N-dimethylaminomethylene cytosin-1'-yl)-1,3-oxathiolane; or pharmaceutically acceptable derivatives thereof, in the form of a racemic mixture or a single enantiomer.
- 16
- 16. The use according to any one of claims 1 to 9, wherein the compound of formula (I) is present as a single enantiomer or as a racemic mixture.
 - 17. The use according to claim 10, wherein the compound of formula (I) is present as its (-) enantiomer.
 - 18. The use according to claim 10, wherein the compound of formula (I) is present as its (+) enantiomer.
 - 19. The use according to any one of claims 1 to 9, wherein the compound is present in either its cis or trans configuration or mixture thereof.
 - 20. The use according to claim 13, wherein the compound of formula (I) is present in its cis configuration.
 - 21. Use of cis-2-hydroxymethyl-5-(5'-fluorocytosin-1'-yl)-1,3-oxathiolane in the manufacture of a medicament for the treatment of a hepatitis B infection.
 - 22. Use of cis-hydroxymethyl-5-(N,N-dimethylaminomethylene cytosin-1'-yl)-1,3-oxathiolane in the manufacture of a medicament for the treatment of hepatitis B infection.
 - 23. The use according to any one of claims 1 to 9, wherein the medicament is adapted for oral, parenteral, rectal, nasal, vaginal, or topical administration.
 - 24. The use according to claim 17, wherein said medicament is administered at a dose of about 0.1 to 750

* mg/kg of bodyweight per day.

19. The use according to claim 17, wherein said medicament is present in dosage unit form in the medicament.
20. The use according to claim 19, wherein the dosage unit form contains approximately 10 to 1500 mg of the compound of formula (I).
21. The use according to any one of claims 1 to 9, wherein said medicament is administered with a pharmaceutically acceptable carrier.
22. The use according to any one of claims 1 to 7, wherein the medicament is administered in combination with a therapeutically active agent selected from the group consisting of: antiviral, antibacterial, antifungal and immunomodulating agents.

18

29

28

39

38

46

50

55



EUROPEAN SEARCH REPORT

Applicant Name

EP 92 30 4530

DOCUMENTS CONSIDERED TO BE RELEVANT		SEARCHED IN CLASS	CLASSIFICATION OF THE APPLICATION (in C.I.P.)
Category	Description of document (in indication, where appropriate, of relevant passages)		
P,X	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 88, 1st October 1991, pages 8495-8499; S.-L. DOONG et al.: "Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues" "Whole document"	1-14,17 -22	A 61 K 31/505 A 61 K 31/52 A 61 K 31/70
P,X	JOURNAL OF ORGANIC CHEMISTRY, vol. 57, 10th April 1992, pages 2217-2219, American Chemical Society; J.W. BEACH et al.: "Synthesis of enantiomERICALLY pure (2'R,5'S)-(-)-1-[2-(Hydroxymethyl)oxetyl]cyclic-5'-yl]cytosine as a potent antiviral agent against hepatitis B virus (HBV) and human immunodeficiency virus (HIV)" "Whole document"	1-14,17 -22	
Y	WO-A-9 014 091 (THE UNITED STATES OF AMERICA) "Abstract; claims"	1-22	A 61 K
Y	WO-A-9 014 079 (THE UNITED STATES OF AMERICA) "Abstract; claims"	1-22	
P,Y	WO-A-9 117 159 (BIOCHEM INTERNATIONAL) "Page 3, last paragraph - page 4, paragraph 1; claims"	1-22	
D,Y	EP-A-0 382 526 (BIOCHEM INTERNATIONAL) "Whole document"	1-22 /-	
The present search report has been drawn up for all classes			
Place of search		Date of conclusion of the search	
THE HAGUE		21-07-1992	GOETZ G.
CATEGORY OF CITED DOCUMENTS			
I: theory or principle underlying the invention E: earlier general document, not published yet, or "not in the public domain" D: document cited in the application L: document cited in other documents A: experimental material P: computer programs			
I: E: D: L: A: P:			



European Patent
Office

EUROPEAN SEARCH REPORT

Application No.

EP 92 30 4530

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (G16 CLA)											
CATEGORY	Description of document (not indication, where appropriate, of relevant passages)	References to claims												
E	EP-A-0 494 119 (BIOCHEM INTERNATIONAL) * Whole document *	1-6, 9- 14, 17- 22												
			TECHNICAL FIELDS SEARCHED (G16 CLA)											
<p>The present search report has been drawn up for all claims</p> <table border="1"> <tr> <td>Place of search</td> <td>Date of completion of the search</td> <td></td> </tr> <tr> <td>THE HAGUE</td> <td>21-07-1992</td> <td>GOETZ G.</td> </tr> <tr> <td colspan="3">CATEGORY OF CITED DOCUMENTS</td> </tr> <tr> <td> <input checked="" type="checkbox"/> previously unknown to this office <input checked="" type="checkbox"/> potentially relevant to this office <input type="checkbox"/> document of the same category <input type="checkbox"/> administrative background <input type="checkbox"/> other patent documents <input type="checkbox"/> prior art </td> <td> T: Theory or principle underlying the invention S: earlier patent documents, not published or not yet filed D: document cited in the application L: document cited for other reasons A: number of the main patent family, corresponding </td> </tr> </table>				Place of search	Date of completion of the search		THE HAGUE	21-07-1992	GOETZ G.	CATEGORY OF CITED DOCUMENTS			<input checked="" type="checkbox"/> previously unknown to this office <input checked="" type="checkbox"/> potentially relevant to this office <input type="checkbox"/> document of the same category <input type="checkbox"/> administrative background <input type="checkbox"/> other patent documents <input type="checkbox"/> prior art	T: Theory or principle underlying the invention S: earlier patent documents, not published or not yet filed D: document cited in the application L: document cited for other reasons A: number of the main patent family, corresponding
Place of search	Date of completion of the search													
THE HAGUE	21-07-1992	GOETZ G.												
CATEGORY OF CITED DOCUMENTS														
<input checked="" type="checkbox"/> previously unknown to this office <input checked="" type="checkbox"/> potentially relevant to this office <input type="checkbox"/> document of the same category <input type="checkbox"/> administrative background <input type="checkbox"/> other patent documents <input type="checkbox"/> prior art	T: Theory or principle underlying the invention S: earlier patent documents, not published or not yet filed D: document cited in the application L: document cited for other reasons A: number of the main patent family, corresponding													